- INVO Bioscience ( NASDAQ: INVO ) said that Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz (HCTM), based in Kuala Lumpur, Malaysia, is making its INVOcell medical device for intravaginal culture (IVC) procedures available to patients.
- ( INVO ) is trading 6.1% higher .
- The move follows the completion of the first IVC case in the country recently with data presented at the Obstetrical and Gynecological Society of Malaysia where it was awarded a prize as a new and innovative fertility treatment.
- The company said HCTM will start offering IVC both in their public and private sectors with an expectation to complete a number of cycles by the end of 2022.
For further details see:
INVO Bioscience launches INVOcell in Malaysia